跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Selective Killing: How Chemotherapy Harms Cancer Cells More Than Normal Cells

1The Selectivity Problem: Why Preferential Killing Is Possible but Imperfect2Proliferation as the Primary Vulnerability: Cell-Cycle Dependence3Antimetabolites and the S-Phase Trap4Microtubule Poisons and Mitotic Arrest5DNA-Damaging Agents: Alkylators, Crosslinkers, and Topoisomerase Poisons6The DNA-Damage Response and the Decision to Die7Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window8Resistance: How Tumors Escape and What It Reveals About Selectivity9Widening the Window: Clinical Strategies That Exploit Selectivity
Antimetabolites and the S-Phase Trap

Where Antimetabolites Cut the Nucleotide Supply Line

1 / 3
Follow the pathway from folate to DNA. Folate must be reduced by dihydrofolate reductase before it can donate a methyl group to thymidylate synthase, which converts dUMP into dTMP. Methotrexate blocks the reductase, so the reduced folate pool collapses and thymidylate synthase has no cofactor. Fluorouracil takes the other route: it becomes FdUMP and traps thymidylate synthase in a stable complex. Notice that both drugs hit different points but converge on the same shortage — no dTMP, no thymidine for DNA. That convergence is why these drugs are grouped together.
0:00 / 0:00

DNA replication in S phase requires a balanced supply of the four deoxynucleotides, and the thymidine nucleotides are the most vulnerable part of that supply because their synthesis depends on a short, linear pathway. Folate enters the pathway in its oxidized form and must be reduced to tetrahydrofolate (THF) by dihydrofolate reductase (DHFR). THF is then converted to 5,10-methylenetetrahydrofolate, which donates the methyl group that thymidylate synthase (TS) uses to convert deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP). The reaction consumes the folate cofactor, leaving dihydrofolate that must be re-reduced by DHFR to sustain the cycle.

Methotrexate binds DHFR with high affinity and blocks this regeneration step. The reduced-folate pool collapses, TS loses its cofactor, and dTMP production falls. 5-Fluorouracil follows a different route to the same enzyme: after intracellular conversion it becomes fluorodeoxyuridine monophosphate (FdUMP), which binds the TS active site and, together with the folate cofactor, forms a stable ternary complex that inactivates the enzyme. Both drugs therefore deplete thymidine nucleotides, but one starves the enzyme of its cofactor while the other traps the enzyme itself.

Pemetrexed and other antifolates inhibit several folate-dependent enzymes at once, including TS and DHFR, which broadens the block. The pyrimidine and purine analogs act one step further downstream or on parallel pathways: cytarabine is phosphorylated to a triphosphate that is incorporated into DNA and terminates chain elongation, and 6-mercaptopurine is converted to a fraudulent purine nucleotide that disrupts purine synthesis and incorporation. The common feature is that each drug is a substrate analog — a molecule close enough to the real substrate to be handled by the same enzymes and transporters, but different enough to jam the reaction.

参考资料

  1. [1]Methotrexate — StatPearls, NCBI Bookshelfncbi.nlm.nih.gov
  2. [2]Fluorouracil — StatPearls, NCBI Bookshelfncbi.nlm.nih.gov
上一页1 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion